OBJECTIVES: To describe prospectively the prevalence and severity of disease-related symptoms, quality of life (QOL) and need for palliative care in patients with advanced pancreatic cancer. PATIENTS AND METHODS: Fifty-one patients treated for advanced pancreatic cancer filled in the Edmonton Symptom Assessment Scale (ESAS) for symptom registration and the EORTC QLQ-C30 and QLQ-PAN26 quality of life questionnaires at first contact (baseline) and the ESAS in the following consultations. Need for palliative interventions were registered. RESULTS: Of the 22 women and 29 men (mean age, 62 years), 20 had locally unresectable cancer, 19 had metastatic disease, and 12 had recurrent disease after curative resection. Forty-six patients died during follow-up (median survival, 99 days). At baseline, patients reported significantly impaired QOL on nine of 15 scales/items (p<0.01) relative to the general population. Fatigue, loss of appetite, and impaired sense of well-being were the most troublesome symptoms on the ESAS, measured to 4.4(+/-2.8)/5.3(+/-2.3), 4.4(+/-3.2)/5.9(+/-2.7), and 4.0(+/-2.9)/4.6(+/-2.7) (mean+/-SD) at baseline and 8 weeks before death, respectively. Forty-four of the 51 (86%) initial consultations and 107 (58%) of the 185 follow-ups (124 clinical and 61 phone-calls) resulted in palliative care interventions, most frequently changes in opioid or laxative medication and dietary advice. CONCLUSIONS: Patients with advanced pancreatic cancer develop several distressing symptoms. ESAS was useful for assessment of symptom prevalence and intensity and is a clinically adequate method for symptom control. A multidisciplinary approach is necessary for the best palliation of symptoms at the time of diagnosis and during follow-up.
OBJECTIVES: To describe prospectively the prevalence and severity of disease-related symptoms, quality of life (QOL) and need for palliative care in patients with advanced pancreatic cancer. PATIENTS AND METHODS: Fifty-one patients treated for advanced pancreatic cancer filled in the Edmonton Symptom Assessment Scale (ESAS) for symptom registration and the EORTC QLQ-C30 and QLQ-PAN26 quality of life questionnaires at first contact (baseline) and the ESAS in the following consultations. Need for palliative interventions were registered. RESULTS: Of the 22 women and 29 men (mean age, 62 years), 20 had locally unresectable cancer, 19 had metastatic disease, and 12 had recurrent disease after curative resection. Forty-six patients died during follow-up (median survival, 99 days). At baseline, patients reported significantly impaired QOL on nine of 15 scales/items (p<0.01) relative to the general population. Fatigue, loss of appetite, and impaired sense of well-being were the most troublesome symptoms on the ESAS, measured to 4.4(+/-2.8)/5.3(+/-2.3), 4.4(+/-3.2)/5.9(+/-2.7), and 4.0(+/-2.9)/4.6(+/-2.7) (mean+/-SD) at baseline and 8 weeks before death, respectively. Forty-four of the 51 (86%) initial consultations and 107 (58%) of the 185 follow-ups (124 clinical and 61 phone-calls) resulted in palliative care interventions, most frequently changes in opioid or laxative medication and dietary advice. CONCLUSIONS:Patients with advanced pancreatic cancer develop several distressing symptoms. ESAS was useful for assessment of symptom prevalence and intensity and is a clinically adequate method for symptom control. A multidisciplinary approach is necessary for the best palliation of symptoms at the time of diagnosis and during follow-up.
Authors: K D Lillemoe; J L Cameron; J M Hardacre; T A Sohn; P K Sauter; J Coleman; H A Pitt; C J Yeo Journal: Ann Surg Date: 1999-09 Impact factor: 12.969
Authors: E J M Nieveen van Dijkum; K F D Kuhlmann; C B Terwee; H Obertop; J C J M de Haes; D J Gouma Journal: Br J Surg Date: 2005-04 Impact factor: 6.939
Authors: P Bachmann; C Marti-Massoud; M P Blanc-Vincent; J C Desport; V Colomb; L Dieu; D Kere; J C Melchior; G Nitenberg; B Raynard; P Roux-Bournay; S Schneider; P Senesse Journal: Br J Cancer Date: 2003-08 Impact factor: 7.640
Authors: Kristin M Sheffield; Casey A Boyd; Jamie Benarroch-Gampel; Yong-Fang Kuo; Catherine D Cooksley; Taylor S Riall Journal: Cancer Date: 2011-04-14 Impact factor: 6.860
Authors: Jia Luo; Jie Jane Chen; Carl Deguzman; Karen Mustian; Megan Insco; George Fisher; Oxana Palesh Journal: J Palliat Med Date: 2014-06 Impact factor: 2.947
Authors: Asta Bye; Marit S Jordhøy; Grete Skjegstad; Oddlaug Ledsaak; Per Ole Iversen; Marianne Jensen Hjermstad Journal: Support Care Cancer Date: 2012-06-10 Impact factor: 3.603
Authors: David B Bekelman; John S Rumsfeld; Edward P Havranek; Traci E Yamashita; Evelyn Hutt; Sheldon H Gottlieb; Sydney M Dy; Jean S Kutner Journal: J Gen Intern Med Date: 2009-03-14 Impact factor: 5.128